DOCSLIB.ORG

2020 Health for Humanity Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2020 Health for Humanity Report 2020 Health for Humanity Report Progress in Sustainability Contents | Message from Our CEO | Our Approach | United in Defeating COVID-19 | Better Health for All | Responsible Business Practices | Reporting Hub Contents Message from Our Chairman and CEO 3 2020 Year in Brief 4 Our Recognitions 5 Our Approach 6 Health for Humanity Strategy & Goals 9 Sustainability Governance 13 Sustainability Priorities 14 United in Defeating COVID-19 15 Caring for Patients 17 Supporting the Front Lines of Care 24 Protecting Employees 25 Supply Chain Resilience 28 Better Health for All 30 Innovation 31 Global Public Health Strategy 35 Access & Affordability 45 Strengthening Health Systems 48 Responsible Business Practices 52 Ethics & Values 53 Our People 60 Product Quality & Safety 74 Environmental Health 79 Responsible Supply Base 90 ABOVE: During the COVID-19 pandemic, Report overview community healthcare workers in Peru Reporting Hub 98 This Report details the progress of the Johnson & Johnson Family traveled door-to-door to reach children with ESG Summary 98 of Companies in sustainability. It is also our primary source of VERMOX Chewable tablets for treatment of Performance Data 98 annual disclosure on environmental, social and governance intestinal worms. The medicine is donated GRI Content Index 98 (ESG) performance and should be reviewed in conjunction by Johnson & Johnson and implemented GRI Culture of Health for Business Framework 98 with disclosures on the ESG Policies & Positions page. Data by INMED Partnerships for Children. SASB Index 98 in this Report cover the period between January 1, 2020, and Photo by INMED Partnerships for Children. TCFD 98 December 31, 2020, unless otherwise noted. Reporting on other FRONT COVER: Jacquelyn W., Senior UNGC Communication on Progress 98 matters specific to financial performance of the Company and its Warehouse Operator, celebrating the CDP Reports 98 subsidiaries can be found in our 2020 Annual Report. For more first outbound shipment of the Johnson & About this Report 99 information and the Cautionary Note Regarding Forward-Looking Johnson COVID-19 vaccine. Independent Assurance Statements 101 Statements, please see About this Report. Glossary 115 To read this report online, visit healthforhumanityreport.jnj.com. References 116 2020 Health for Humanity Report Contents | Message from Our CEO | Our Approach | United in Defeating COVID-19 | Better Health for All | Responsible Business Practices | Reporting Hub Message from Our Chairman and CEO GRI 102-14 To Our Global Community: chains, and launching a first-of-its-kind medical device ecosystem to take on the challenges of tomorrow. for the management of persistent atrial fibrillation. And, as always, we will hold ourselves to a high level We all know from firsthand experience that 2020 Delivering on our responsibilities to a healthy planet, of transparency and accountability through reports was a year of profound upheaval and uncertainty. we made progress on reducing our carbon footprint, such as this one and our annual Janssen U.S. It was also, however, a clarifying moment for us at including achieving more than 50% use of renewable Transparency Report. Johnson & Johnson. electricity globally. As we grappled with the wide-ranging impacts of Throughout 2020, bearing witness to the way the the COVID-19 pandemic and the ongoing economic pandemic revealed weaknesses in our public health volatility that threw into stark relief the issues of racial systems and pushed businesses to do more to create injustice and health inequities, one thing was certain: healthier, more equitable communities was sometimes a when it comes to global public health, the stakes could humbling experience—but it was also an inspiration. not be higher. While solving the most pressing global health challenges is never easy, the once-in-a-generation I’m pleased to be able to say that these challenges of confluence of these crises underscored the complexity 2020 only enhanced our commitment to—and continued that organizations like ours must navigate if we truly focus on—creating long-term value for all stakeholders want to make the maximum positive impact on human by integrating social considerations, environmental Alex Gorsky connecting with employees during a virtual visit health. sustainability and good governance into every aspect to our Shanghai and Beijing offices. of our business. From launching the Our Race to At Johnson & Johnson, taking on even the most Health Equity platform to address the root causes of I know we will continue to do our part through daunting healthcare challenges has been at the core healthcare inequity in the United States, to deepening whatever unknowable new challenges and upheavals of who we are for 135 years. And while living up to our commitments to address complex issues like lie ahead, because we will always be able to draw our commitments embodied in Our Credo has always smoking cessation, to environmental health innovations upon our ultimate strength: the remarkable people required constant evolution and innovation, the last year to make our packaging easier to recycle or reuse through of Johnson & Johnson. In an extraordinary year, our demanded that we embrace radically new ways of doing the Healthy Lives initiative from Johnson & Johnson 136,000-plus global employees embraced radically business and even greater heights of purpose-driven Consumer Health, we have kept our sights firmly set on new ways of working with greater agility than ever collaboration through public–private partnerships. catalyzing lasting change. before. Each individual’s ingenuity and resilience are As we detail in this Report, the significant challenges of what allowed us to go above and beyond for all our To help lead the world into a brighter post-COVID-19 2020 did not deter us from accomplishing many of our stakeholders. I could not be prouder of what Johnson & future where healthier families flourish in healthier key goals. Johnson employees showed the world is possible— societies on a healthier planet, we know we must or more optimistic about what their passion and While much of the world’s attention was on our capitalize on the incredible momentum we’ve unleashed perseverance will help us achieve in the future. leadership in the fight against theCOVID-19 at Johnson & Johnson this past year. pandemic—culminating in the deployment of our Building on our Health for Humanity 2020 Goals—the Janssen COVID-19 vaccine this year—we also achieved successes and shortcomings of which are detailed in this our Health for Humanity 2020 Goals of fighting HIV and Report—we are launching even more ambitious goals tuberculosis, as well as accelerating broader access to for 2025 that will enable us to continue living into Our our Ebola vaccine for those most in need. We brought Purpose as we make further contributions to 11 of the 17 this same agility to our work on behalf of our patients United Nations 2030 Sustainable Development Goals. and customers in areas as diverse as advancing the Given how essential collaboration was to our shared Alex Gorsky science around the treatment of multiple myeloma, progress in 2020, we’re actively expanding on many of Chairman, Board of Directors deploying technological innovations and application of our historic partnerships across the entire healthcare and Chief Executive Officer data science to safeguard critically important supply 2020 Health for Humanity Report 3 Contents | Message from Our CEO | Our Approach | United in Defeating COVID-19 | Better Health for All | Responsible Business Practices | Reporting Hub 2020 Year in Brief OUR NEW COMMITMENTS AND GOALS $100 million $800 million ambitious Health for Humanity 2025 Goals committed over the next five years in the U.S. to help committed through 2030 to advance our Healthy addressing pandemics and epidemics, global health eliminate health inequities for people of color Lives Mission, to make our Consumer Health equity, our people, planet and partners products more sustainable 21 OUR IMPACT People We Serve Combating COVID-19 Advancing Breakthrough Science for HIV Preventing Future Ebola Within a year, began manufacturing our single-shot Received European Commission Marketing Outbreaks COVID-19 vaccine, now authorized for emergency Authorization for REKAMBYS (rilpivirine injection) to Received European Commission use by the U.S. FDA, granted a Conditional Marketing be used with ViiV Healthcare’s Vocabria (cabotegravir Marketing Authorization for 11 Authorization by the European Commission, and injection) as the first-ever complete, long-acting Photo by Rwanda Ebola vaccine regime for the issued an Emergency Use Listing by the World Health injectable HIV treatment regimen Ministry of Health. prevention of Ebola Virus Disease Organization (WHO) Treating Atrial Fibrillation Partnering to Stop Smoking Expanding Access to MDR-TB Treatment Received CE mark approval for QDOT MICRO As part of the Access Initiative for Quitting Tobacco, Collaborated with the Stop TB Partnership’s Global Catheter, next-generation high-power, short-duration launched by the WHO to reduce smoking rates around Drug Facility to develop and implement a novel access ablation catheter for the treatment of atrial fibrillation the world, Johnson & Johnson Consumer Health framework for SIRTURO (bedaquiline) for 135+ low- donated nicotine replacement therapy patches and middle-income countries Employees Communities & Planet Shareholders Over 100 46% $2.6 billion 54% of our $12.2 billion medically trained employees of management
Load more

Recommended publications
  • Access to Medicine Index Scoping Report & Stakeholder Review
    THE APPROACH TAKEN TO Access To Medicine Index ESTABLISH THE ACCESS TO MEDICINE INDEX Scoping Report & FRAMEWORK Background Research The Access To Medicine Index project Stakeholder Review builds on a large body of work published on this issue in recent years. Innovest has February 2007 collected and reviewed the latest academic, industry, and other third-party reports on access to medicines (ATMs) and related issues. Report prepared by The Innovest Healthcare Team: Veronique Menou, Adam Savitz and Katharine Preston. ATMs Questionnaire A questionnaire was designed to help Access To Medicine Index Framework identify the key issues to be included in an evaluation of healthcare companies’ ATMs strategies and performance based 20% Access to Medicines Management on the background research. The questionnaire was delivered to over 200 20% Research & Development into Neglected Diseases leading ATMs experts around the globe. This key stakeholder group included academics, consultants, investors, 18% Equitable Pricing government representatives, and non- governmental organizations (NGOs). 15% Patents & Licensing Stakeholder Roundtables 10% Policy Influence & Lobbying Stakeholder roundtables were held in London and New York to discuss and debate the questionnaire results and 7% Drug Donations refine ATMs indicators. Each stakeholder roundtable included 5% Philanthropic Activities representatives from the stakeholder groups, who shared their expertise and 5% Ethical Promotion & Marketing Activities continued to provide input during the Access To Medicine Index building This table includes the eight most relevant criteria, ranked in order of importance, as indicated by the percentage weighting. This criteria will be used to evaluate each pharmaceutical company’s performance during the CONTINUED ON NEXT PAGE… benchmarking phase.
    [Show full text]
  • Business Case Study Competitive Advantage and CSR
    Business Case Johnson & Johnson Is there a connection between being socially responsible and building sustainable competitive advantage? ©2008 National Safety Council Johnson & Johnson Business Case Study Competitive Advantage and CSR BUSINESS CASE SCENARIO Perry Somers, a second-year MBA student, thoroughly enjoyed his summer internship at one of Wall Street’s top investment banks. His mentor had taught him the value of looking beyond standard financial analyses to truly understand the underlying logic that supports an organization’s decisions and their ultimate impact on the long-term success of a company. The intense research and systematic analysis required to gain unique insights appealed to the engineer in him (Perry graduated cum laude from an engineering program five years ago). Perry’s summer experience had also solidified his commitment to famed economist Milton Friedman’s claim that the social responsibility of business is to increase its profits.i While many of his classmates were off at rallies and conferences advocating for more corporate involvement in social causes, Perry stayed focused on his prime reason for attending business school: learning how to create value for shareholders. Perry was especially energized when he learned that his business school had named William Weldon, CEO of Johnson & Johnson, its Business Leader of the Year. Perry had studied the pharmaceutical industry during his internship and had a number of lingering questions. He hoped to have an opportunity to ask Mr. Weldon those questions when the CEO came to campus to receive the award and give his acceptance speech. As Perry reviewed his notes from the summer, Johnson & Johnson’s stated commitment to “socially responsible” policies and practices raised questions for him.
    [Show full text]
  • Annual Report
    ANNUAL REPORT 2019 MARCH 2020 To Our Shareholders Alex Gorsky Chairman and Chief Executive Officer By just about every measure, Johnson & These are some of the many financial and Johnson’s 133rd year was extraordinary. strategic achievements that were made possible by the commitment of our more than • We delivered strong operational revenue and 132,000 Johnson & Johnson colleagues, who adjusted operational earnings growth* that passionately lead the way in improving the health exceeded the financial performance goals we and well-being of people around the world. set for the Company at the start of 2019. • We again made record investments in research and development (R&D)—more than $11 billion across our Pharmaceutical, Medical Devices Propelled by our people, products, and and Consumer businesses—as we maintained a purpose, we look forward to the future relentless pursuit of innovation to develop vital with great confidence and optimism scientific breakthroughs. as we remain committed to leading • We proudly launched new transformational across the spectrum of healthcare. medicines for untreated and treatment-resistant diseases, while gaining approvals for new uses of many of our medicines already in the market. Through proactive leadership across our enterprise, we navigated a constant surge • We deployed approximately $7 billion, of unique and complex challenges, spanning primarily in transactions that fortify our dynamic global issues, shifting political commitment to digital surgery for a more climates, industry and competitive headwinds, personalized and elevated standard of and an ongoing litigious environment. healthcare, and that enhance our position in consumer skin health. As we have experienced for 133 years, we • And our teams around the world continued can be sure that 2020 will present a new set of working to address pressing public health opportunities and challenges.
    [Show full text]
  • Caring for the World . . .One Person at a Time™ Inspires and Unites the People of Johnson & Johnson
    OUR CARING TRANSFORMS 2007 Annual Report Caring for the world . .one person at a time™ inspires and unites the people of Johnson & Johnson. We embrace research and science—bringing innovative ideas, products and services to advance the health and well-being of people. Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world. The people in our more than 250 companies come to work each day inspired by their personal knowledge that their caring transforms people’s lives . one person at a time. On the following pages, we invite you to see for yourself. Our Caring Transforms ON THE COVER Johnson & Johnson is founding sponsor and continues to support Safe Kids Worldwide®. For 20 years the organization has grown, now teaching prevention as a way to save children’s lives in 17 countries around the world. In Brazil, Nayra Yara da Paz de Jesus carefully washes her hands, a safe, healthy habit she and other children are learning from a local Safe Kids® program. Find out more in our story on page 22. C H A I R M A N ’ S L E T T E R To Our Shareholders Caring for the health and well-being of people throughout the world is an extraordinary business. It is a business where people are passionate about their work, because it matters. It matters to their families, to their communities and to the world. It is a business filled with tremendous opportunity for leadership and growth in the 21st century; a business where unmet needs still abound and where people around the world WILLIAM C.
    [Show full text]
  • The Access to Medicine Index 2014 Access to Medicine Foundation Scheepmakersdijk 5A NL-2011 AS Haarlem the Netherlands
    The Access to Medicine Index 2014 Access to Medicine Foundation Scheepmakersdijk 5a NL-2011 AS Haarlem The Netherlands On behalf of the Access to Medicine Foundation, Please contact Jayasree K. Iyer, Head of Research E [email protected] and [email protected] T +31 (0)23 53 39 187 W www.accesstomedicineindex.org Funders This report was made possible by financial support from the Bill & Melinda Gates Foundation, the UK Department for International Development (DFID), and the Dutch Ministry of Foreign Affairs. The Access to Medicine Index 2014 Access to Medicine Foundation November 2014 Access to Medicine Index 2014 Acknowledgements The 2014 Access to Medicine Index 2014 is made possible through the collaborative team effort of several experts, authors, researchers and analysts.1 The Foundation is grateful for their contributions and expertise, and would like offer thanks to those individuals who provided valuable feedback throughout the development of the 2014 Index. Funders Bill & Melinda Gates Foundation UK Department for International Development (DFID) The Netherlands Ministry of Foreign Affairs Expert Review Committee The Access to Medicine Hans Hogerzeil (Chair) Research team Natacha Dimitrijevic Jayasree K. Iyer Marja Esveld Delphi Coppens Regina Kamoga Danny Edwards Richard Laing Tara Prasad Dennis Ross-Degnan Laurien Rook Dilip Shah Lisanne Urlings Peter Shelby Editorial team Technical subcommittees Hans Hogerzeil Peter Beyer Jayasree K. Iyer Esteban Burrone Anna Massey Jennifer Dent Ed Monchen Jaime Espin Emma Ross Michele Forzley Suzanne Wolf Javier Guzman Warren Kaplan Data collection and scoring Jillian Kohler Sustainalytics Niranjan Konduri Andrea van Dijk Prashant Yadav Teodora Blidaru Radoslav Georgiev Reviewers Hazel Goedhart Esteban Burrone Vikram Puppala Jennifer Dent Hans Hogerzeil Report Design Richard Laing Explanation Design BV Jillian Kohler Niranjan Konduri IT Efficiency Online BV Other contributors Gbola Amusa Printers Sara Brewer Drukkerij Aeroprint Theo K.
    [Show full text]
  • 2014 Annual Report • 1 Management’S Discussion and Analysis of Results of Operations and Financial Condition
    ANNUAL REPORT 2014 MARCH 2015 TO OUR SHAREHOLDERS ALEX GORSKY Chairman, Board of Directors and Chief Executive Officer I am often asked what led me to work in Perhaps there’s no better proof of that than the THERE IS health care and why I chose to spend most success Johnson & Johnson achieved in 2014. NO COMPANY of my career at Johnson & Johnson. From my We delivered solid financial results, with full-year BETTER first job at Janssen, the flagship company of 2014 sales of $74.3 billion and adjusted net POSITIONED our Pharmaceutical segment, to my current earnings of $17.1 billion†, while also continuing TO HELP MEET role as the company’s Chairman and CEO to make investments to accelerate growth for THESE URGENT 25 years later, the answer always begins the long term. NEEDS THAN with Our Credo. JOHNSON & And while I am pleased with our performance, JOHNSON A simple yet powerful document penned we know that we can never rest, because by General Robert Wood Johnson, the son of providing sustainable high-quality health care our founder and our company’s first Chairman, is one of our society’s greatest challenges. Our Credo outlines the Company’s commitments and responsibilities to the people and This is an unprecedented era in human history. communities we touch every day with our The historic aging rate of the world’s population, products and services. For more than 70 years along with a growing middle class around the now, it has served as the moral compass of world, brings dramatically greater demand for Johnson & Johnson – ensuring we never lose higher quality health care; and governments sight of our strong values and the important and health systems must manage this with needs of the many stakeholders we serve.
    [Show full text]
  • Access to Medicine Index 2018 Methodologyaccess to REPORT Medicine Index 2018 Methodology Report 2017
    Access to Medicine Foundation Access to Medicine Index 2018 METHODOLOGYAccess to REPORT Medicine Index 2018 Methodology Report 2017 ACCESS TO MEDICINE FOUNDATION September 2017 1 Methodology for the 2018 Access to Medicine Index ACKNOWLEDGEMENTS The Access to Medicine Foundation would like to thank the following people and organisations for their contributions to this report. FUNDERS Bill & Melinda Gates Foundation The UK government The Netherlands Ministry of Foreign Affairs EXPERT REVIEW COMMITTEE Hans Hogerzeil (Chair) Sanne Frost-Helt Fumie Griego Suzanne Hill Frasia Karua Dennis Ross-Degnan Dilip Shah Yo Takatsuki Joshua Wamboga Prashant Yadav TECHNICAL SUBCOMMITTEES RESEARCH TEAM EDITORIAL TEAM Esteban Burrone Danny Edwards Anna Massey Nick Chapman Beth Boyer Deirdre Cogan Jennifer Dent Clarke Cole Michele Forzley Luca Genovese Warren Kaplan Catherine Gray Jillian Kohler Nestor Papanikolaou Niranjan Konduri Tara Prasad Stine Trolle ADDITIONAL CONTRIBUTORS We would like to thank the many other experts who contributed their views to the development of this methodology (see page 56). ACCESS TO MEDICINE FOUNDATION The Access to Medicine Foundation is an independent non-profit org- anisation based in the Netherlands. It aims to advance access to medi- cine in low- and middle-income countries by stimulating and guiding the pharmaceutical industry to play a greater role in improving access. Naritaweg 227-A 1043 CB, Amsterdam The Netherlands For questions about this report, please contact Danny Edwards, Research Programme Manager [email protected] +31 (0) 20 215 35 35 www.accesstomedicineindex.org 2 Access to Medicine Foundation A good practice framework There is no simple blueprint for making medicine accessible During ten years of research, we have identified real progress to all who need them.
    [Show full text]
  • Access to Medicine Index 2018 Access to Medicine Foundation
    Access to Medicine Index 2018 Access to Medicine Foundation Access to Medicine Index 2018 ACCESS TO MEDICINE FOUNDATION November 2018 1 Access to Medicine Index 2018 ACKNOWLEDGEMENTS The Access to Medicine Foundation would like to thank the following people and organisations for their contributions to this report. FUNDERS UK Department for International Development The Dutch Ministry of Foreign Aff airs Bill & Melinda Gates Foundation EXPERT REVIEW COMMITTEE RESEARCH TEAM Hans Hogerzeil – Chair Danny Edwards Sanne Frost Helt Beth Boyer Fumie Griego Clarke Cole Suzanne Hill Myriam Diallo Frasia Karua Karrar Karrar Dennis Ross-Degnan Alex Kong Dilip Shah Nestor Papanikolaou Yo Takatsuki Stine Trolle Joshua Wamboga Margo Warren Prashant Yadav Mariska van der Zee REVIEWERS EDITORIAL TEAM Hans Hogerzeil Anna Massey Gabrielle Breugelmans Deirdre Cogan Esteban Burrone Emma Ross Jennifer Dent Michele Forzley ADDITIONAL CONTRIBUTORS Frasia Karua We would like to thank the many other experts Niranjan Konduri who contributed their views to the development of this report (see Appendix XVI). ACCESS TO MEDICINE FOUNDATION The Access to Medicine Foundation is an independent non-profi t organisation based in the Netherlands. It aims to advance access to medicine in low- and middle-income countries by stimulating and guiding the pharmaceutical industry to play a greater role in improving access. Naritaweg 227-A 1043 CB, Amsterdam The Netherlands For questions about this report, please contact Danny Edwards, Research Programme Manager [email protected] +31 (0) 20 215 35 35 www.accesstomedicineindex.org 2 Access to Medicine Foundation How to radically ramp up access to healthcare How can we radically ramp up access to healthcare worldwide? This 6th Access to Medicine Index shows where pharmaceutical companies are currently focusing their efforts to improve access.
    [Show full text]
  • P a T I E N T S Innovation P a R T N E
    Annual Report 2018 PATIENTS INNOVATION PARTNERS In cancer, modern care helps Advanced analytics enable us to Roche is expanding its colla b­ where no effective treatments were create a wealth of new data insights orations, combining its own available previously. Innovative and opportunities across the strengths with the unique tools of therapies allow this woman on entire product lifecycle and R&D its partners to elevate personalised the cover picture to carry on with value chain to ultimately improve healthcare to a new level for many her life. See back cover for more. outcomes for patients. more patients. Keith Terry, Genentech, USA “This was an emotional hire for me.” I am the Medical Doctor Talent Scout for Genentech with family and friends—and not dwell on the in South San Francisco and work closely with our negative. It has taught me to stay in the moment. Product Development Neuroscience team. Ironically, There have been some down times too, when I I had a big win with the hiring of a senior medical experienced a relapse. I felt so fatigued that it was director for Ocrevus, the medication that I currently an effort just to breathe. It is difficult to imagine use to treat my multiple sclerosis (MS). This was an this level of fatigue until you have experienced it. emotional hire for me. This illness has really increased my capacity for empathy for those that are ill. I was diagnosed with multiple sclerosis 16 years ago at the age of 37. I had been experiencing extreme But overall there have been many positives.
    [Show full text]
  • Johnson & Johnson
    TRILLIUM ASSET MANAGEMENT January 19, 2021 Via e-mail at [email protected] Securities and Exchange Commission Office of the Chief Counsel Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: Request by Johnson & Johnson to omit Proposal submitted by submitted by Trillium Asset Management (“Trillium”) on behalf of Christopher and Anne Ellinger and co-filers. Ladies and Gentlemen, This is a supplement to Trillium Asset Management LLC’s (acting on behalf Christopher and Anne Ellinger and co-filers (together, the “Proponents”)) January 6 and 10, 2021 letters and in response to Johnson & Johnson’s (“J&J”, “JNJ”, or the “Company”) December 16, 2020 and January 15, 2021 letters regarding a shareholder proposal (the "Proposal) submitted to the Company. The Proposal asks J&J to publish a third-party audit on racial impact and civil rights. 1. Johnson & Johnson has misrepresented the essential element of the Proposal. The Company asserts that “the essential objective of the Proposal is to obtain a report on ways Johnson & Johnson can improve the racial impact of its policies, practices, products and services.” That description entirely ignores the third-party audit request as the center of the Proposal. This failure to accurately and fairly describe the Proposal – effectively an effort to twist the words of the Proposal – is fatal for the Company’s argument. As is abundantly clear in a plain reading of the proposal the request is for: a third-party audit (within a reasonable time, at a reasonable cost, and excluding confidential/proprietary information) to review its corporate policies, practices, products, and services, above and beyond legal and regulatory matters; to assess the racial impact of the company's policies, practices, products and services; and to provide recommendations for improving the company’s racial impact.
    [Show full text]
  • The Role of Intellectual Property in Local Production in Developing
    Monitoring and Intellectual R&D, Technology Financing Property and Trade Innovation Transfer Improving Access Reporting Opportunities and challenges The role of intellectual property in local production in developing countries The role of intellectual property in local production in developing countries Opportunities and challenges WHO Library Cataloguing-in-Publication Data The role of intellectual property in local production in developing countries: opportunities and challenges. 1.Intellectual Property. 2.Technology Transfer. 3.Drugs, Essential. 4.Patents. 5.Developing Countries. I.World Health Organization ISBN 978 92 4 151030 1 (NLM classification: QV 704) © World Health Organization 2016 All rights reserved. Publications of the World Health Organization are available on the WHO website (http://www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non- commercial distribution– should be addressed to WHO Press through the WHO website (http:// www.who.int/about/licensing/copyright_form/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • 2002 Annual Report Three Years in Brief–Worldwide
    2002 Annual Report Three Years in Brief–Worldwide % Change (Dollars in Millions Except Per Share Figures) 2002 2001 2000 2002 2001 Sales to customers $36,298 $ 32,317 29,172 12.3 10.8 Net earnings* 6,597 5,668 4,953 16.4 14.4 Cash dividends paid 2,381 2,047 1,724 16.3 18.7 Shareholders’ equity 22,697 24,233 20,395 (6.3) 18.8 Percent return on average shareholders’ equity 28.1 25.4 26.5 – – Per Share Net earnings - basic 2.20 1.87 1.65 17.6 13.3 - diluted 2.16 1.84 1.61 17.4 14.3 Cash dividends paid 0.795 0.70 0.62 13.6 12.9 Shareholders’ equity 7.65 7.95 6.77 (3.8) 17.4 Market price (year-end close) 53.11 59.86 52.53 (11.3) 14.0 Average shares outstanding (millions) - basic 2,998.3 3,033.8 2,993.5 (1.2) 1.3 - diluted 3,054.1 3,099.3 3,099.2 (1.5) 0.0 Number of employees (thousands) 108.3 101.8 100.9 6.4 0.9 * Net earnings and earnings per share for 2002 include In-process research and development (IPR&D) charges of $189 million or .07 diluted earnings per share related to the acquisitions of Tibotec-Virco N.V. and Obtech Medical AG. Excluding the impact of these charges, 2002 net earnings increased 16.8% over 2001. Net earnings and earnings per share in 2001 and 2000 include $231 million or .07 diluted earnings per share and $45 million or .02 diluted earnings per share, respectively, related to IPR&D and ALZA merger costs in 2001 and IPR&D net of restructuring gains in 2000.
    [Show full text]